Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 183

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study

Open access
Deodhar, Atul, Gottlieb, Alice B, Boehncke, Wolf-Henning, Dong, Bin, Wang, Yuhua, Zhuang, Yanli, Barchuk, William, Xu, Xie L, Hsia, Elizabeth C, AELION, Jacob, AMARELO-RAMOS, Juan, BALSA, Alejandro, BERGHEA, Florian, BRZEZICKI, Jan, BURNETTE, Michael, FRETZIN, Scott, GARCÍA-CARAZO, Sara, GLADSTEIN, Geoffrey, GOMEZ-REINO, Juan, GOODERHAM, Melinda, GONZÁLEZ-FERNÁNDEZ, Carlos, GOTTLIEB, Alice, GRATACOS, Jordi, HAALAND, Derek, KAMALOVA, Rima, LESZCZYNSKI, Piotr, MARTIN-MOLA, Emilio, MASLYANSKY, Alexey, NAVARRO, Federico, OPRIS, Daniela, PAPP, Kim, PERLAMUTROV, Yuriy, PHILIPP, Sandra, RACEWICZ, Artur, REBROV, Andrey, RELL-BAKALARSKA, Maria, ROSMARIN, David, RUBBERT-ROTH, Andrea, SHERGY, William, SHIRINSKY, Ivan, SONIN, Dmitry, STANISLAV, Marina, SUKHAREV, Alexey, TEMNIKOV, Vadim, VINOGRADOVA, Irina, WAYTZ, Paul, YAKUSHEVICH, Vladimir · 2018 · The Lancet

Abstract

BACKGROUND Guselkumab, a human monoclonal antibody that binds to the p19 subunit of interleukin 23, has been approved for the treatment of moderate-to-severe psoriasis. Psoriatic arthritis is a common comorbidity of psoriasis with an umet need for novel treatments. We assessed the efficacy and safety of guselkumab in patients with active psoriatic arthritis. METHODS We did a randomised, double-blind, placebo-controlled, phase 2a trial at 34 rheumatology and dermatology practices in Canada, Germany, Poland, Romania, Russia, Spain, and the USA. Eligible participants were aged 18 years or older with active psoriatic arthritis and plaque psoriasis affecting at least 3% of their body surface area, with three or more of 66 tender joints and three or more of 68 swollen joints, who had an inadequate response or intolerance to standard treatments. We randomly assigned patients (2:1) via a central interactive web-response system using computer-generated permuted blocks with a block size of six, stratified by previous anti-tumour necrosis factor-α use, to receive subcutaneous guselkumab 100 mg or placebo at week 0, week 4, and every 8 weeks thereafter for 24 weeks. Patients, investigators, and site staff were masked to treatment assignment until final database lock at week 56. At week 16, patients with less than 5% improvement in swollen and tender joint counts were eligible for early escape to ustekinumab. At week 24, the remaining placebo-treated patients crossed over to receive guselkumab 100 mg at weeks 24, 28, 36, and 44 and guselkumab-treated patients received a placebo injection at week 24, followed by guselkumab injections at weeks 28, 36, and 44. The primary endpoint was the proportion of patients with at least 20% improvement at week 24 in signs and symptoms of psoriatic arthritis according to American College of Rheumatology criteria (ACR20) in the modified intention-to-treat population (ie, all randomly assigned patients who received at least one dose of study treatment). Safety analyses included patients according to the study drug received. This study is registered with ClinicalTrials.gov, number NCT02319759. FINDINGS Between March 27, 2015, and Jan 17, 2017, we randomly assigned 149 patients to treatment: 100 to guselkumab and 49 to placebo. 17 (35%) of 49 patients in the placebo group and ten (10%) of 100 patients in the guselkumab group were eligible for early escape to ustekinumab at week 16. 29 (59%) of 49 patients in the placebo group crossed over and received guselkumab at week 24. Three (6%) of 49 patients in the placebo group, one (3%) of 29 patients who crossed over from placebo to guselkumab, and six (6%) of 100 patients in the guselkumab group discontinued study treatment before week 44. 58 (58%) of 100 patients in the guselkumab group and nine (18%) of 49 patients in the placebo group achieved an ACR20 response at week 24 (percentage difference 39·7% [95% CI 25·3-54·1]; p<0·0001). Between week 0 and week 24, 36 (36%) of 100 guselkumab-treated patients and 16 (33%) of 49 placebo-treated patients had at least one adverse event. The most frequent adverse event was infection in both groups (16 [16%] of 100 patients in the guselkumab group vs ten [20%] of 49 patients in the placebo group). The prevalence of adverse events between week 0 and week 56 in guselkumab-treated patients (51 [40%] of 129) indicated no disproportional increase with longer guselkumab exposure. No deaths occurred. INTERPRETATION Guselkumab, a novel anti-interleukin 23p19 antibody, significantly improved signs and symptoms of active psoriatic arthritis and was well tolerated during 44 weeks of treatment. The results of this study support further development of guselkumab as a novel and comprehensive treatment in psoriatic arthritis. FUNDING Janssen Research & Development.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(18)30952-8

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 183

Metadata

Authors
Deodhar, A., Gottlieb, A. B., Boehncke, W.-H., Dong, B., Wang, Y., Zhuang, Y., Barchuk, W., Xu, X. L., Hsia, E. C., AELION, J., AMARELO-RAMOS, J., BALSA, A., BERGHEA, F., BRZEZICKI, J., BURNETTE, M., FRETZIN, S., GARCÍA-CARAZO, S., GLADSTEIN, G., GOMEZ-REINO, J., GOODERHAM, M., GONZÁLEZ-FERNÁNDEZ, C., GOTTLIEB, A., GRATACOS, J., HAALAND, D., KAMALOVA, R., LESZCZYNSKI, P., MARTIN-MOLA, E., MASLYANSKY, A., NAVARRO, F., OPRIS, D., PAPP, K., PERLAMUTROV, Y., PHILIPP, S., RACEWICZ, A., REBROV, A., RELL-BAKALARSKA, M., ROSMARIN, D., RUBBERT-ROTH, A., SHERGY, W., SHIRINSKY, I., SONIN, D., STANISLAV, M., SUKHAREV, A., TEMNIKOV, V., VINOGRADOVA, I., WAYTZ, P., & YAKUSHEVICH, V.
Venue
The Lancet
Publisher
Elsevier BV
Published
2018-06
Volume
391
Issue
10136
Pages
2213-2224
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2805265384
Cited by
183
References
3
FWCI
21.65
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study. https://app.cochat.ai/papers/10.1016/s0140-6736(18)30952-8
The paper
Deodhar, A., Gottlieb, A. B., Boehncke, W.-H., Dong, B., Wang, Y., Zhuang, Y., Barchuk, W., Xu, X. L., Hsia, E. C., AELION, J., AMARELO-RAMOS, J., BALSA, A., BERGHEA, F., BRZEZICKI, J., BURNETTE, M., FRETZIN, S., GARCÍA-CARAZO, S., GLADSTEIN, G., GOMEZ-REINO, J., . . . YAKUSHEVICH, V. (2018). Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study. The Lancet. https://doi.org/10.1016/s0140-6736(18)30952-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.